Millicent Pharma owns the US licensing rights to Intrarosa, a non-estrogen vaginal insert indicated for moderate to severe dyspareunia. It also manufactures and promotes Femring, a 3 month vaginally delivered ring indicated for moderate to severe vasomotor symptoms and symptoms of VVA.